Immunocellular Therapeutics Ltd., of Los Angeles, presented data from the phase I trial of ICT-121 in patients with recurrent glioblastoma, showing that six of 20 patients are alive, as of the April 2017 cut-off, with survival ranging from 10 months to 24 months.